From the smallest biotech to the biggest pharmaceutical stock, The Motley Fool's Market Check-Up covers the health-care sector's biggest headlines, hottest market movers, and Obamacare's ongoing rollout.
In this segment from Monday's episode, health-care analyst David Williamson takes a look at Novartis (NYSE: NVS ) and its announcement that it will be selling off its blood-borne pathogen diagnostics business to the Barcelona-based company Grifols for $1.7 billion. David takes a look at how this move works into the company's broader strategy, why he thinks it was a great sale for Novartis, and what he thinks of the stock going forward.
More Foolish insight
The best way to play the biotech space is to find companies that shun the status quo and instead discover revolutionary, groundbreaking technologies. In the Motley Fool's brand-new FREE report "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that big pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.
Follow David on Twitter @MotleyDavid.